Insmed’s stock rallies on PAH data; Unicycive aims to resolve CDMO issues
Plus, news about AriBio, Arcera, Molecular Partners, Valneva, MacroGenics, Sagard Healthcare Partners, Quell Therapeutics, AstraZeneca, Guardian Bio, Lucy Therapeutics, Argenica, and Gilead’s Tmunity:...
View ArticleEndpoints livestream: RFK Jr. fired the CDC's vaccine panel, and what happens...
Today on Post-Hoc Live, we’re going to dig into HHS Secretary Robert F. Kennedy Jr.’s controversial decision to fire all members of the CDC’s expert vaccine panel, known as ACIP. Yesterday, Kennedy...
View ArticleFDA places hold on Gilead's studies of HIV treatment pill combo
The FDA ordered Gilead to pause studies of two long-acting HIV pills after "a subset of participants" experienced decreases in their immune cell counts, which could be a sign that the immune system is...
View ArticleFDA chief Makary says he wasn’t involved in decision to fire ACIP members
FDA Commissioner Marty Makary said he wasn’t involved in HHS Secretary Robert F. Kennedy Jr.'s decision to fire every member of a key CDC expert panel that guides national vaccine policy. Makary's...
View ArticleArgenx says its drug Vyvgart looks promising in two more autoimmune diseases
The Dutch biotech argenx has big plans for its autoimmune disease drug Vyvgart, which is approved for three conditions and is being tested in a dozen more. On Tuesday evening, it announced ...
View ArticleVertex lays off 125 workers after type 1 diabetes cell therapy failed study...
Vertex Pharmaceuticals is letting go of 125 employees in Rhode Island after a clinical disappointment for its Phase 1/2 type 1 diabetes program. The Boston-based drugmaker is consolidating three of its...
View ArticleSpliceBio gets $135M shortly after starting first clinical trial
In the difficult field of gene therapies, some biotech startups are still reeling in large amounts of capital. Barcelona-based SpliceBio is the latest. The 40-employee upstart bagged a $135 million...
View ArticleBasecamp Research CEO on fixing the 'data wall' in AI bio
From hiking through rainforests to diving into the ocean's depths, the scientist-explorers of Basecamp Research have scoured the Earth's extremes to sample and study biological life. The research...
View ArticleBMS’ RayzeBio bags rights for Philochem’s radiopharma asset for $350M upfront
Bristol Myers Squibb’s subsidiary RayzeBio is spending $350 million upfront to license an early-stage radiopharmaceutical candidate for prostate cancer from Philochem. RayzeBio will get global rights...
View ArticleNovo marks seventh cardiometabolic deal of the year with Deep Apple Therapeutics
Novo Nordisk has been on a dealmaking spree this year to assuage concerns about the future of its obesity and cardiometabolic drugs. The Danish drugmaker's latest partner of choice is Apple Tree ...
View ArticleReality check: Unpacking the $150B GLP-1 market forecasts
Market expectations for GLP-1 agonists have been high for some time. But in the past year, sales forecasts have gone stratospheric. Last month, Morgan Stanley Research upped its 2035 peak estimate for...
View ArticleVaxart shares rise after reporting norovirus vaccine data
A small vaccine maker's stock price shot up Wednesday after releasing new data in the same week that vaccine R&D is the focus of attention. Vaxart {$VXRT} saw its shares surge 45% at market open ...
View ArticleLilly pledges more than $650M to muscle health biotech; Cogent gets $50M
Plus, news about Cellectar Biosciences, Bausch + Lomb, Elkedonia, Pharmazz and Roche: Eli Lilly turns to muscle health biotech: The drugmaker and Juvena Therapeutics will work on treatments for ...
View ArticleCabaletta Bio shares CAR-T results in three autoimmune conditions
Cabaletta Bio reported that its CAR-T therapy led to clinical improvements and in some cases remission in three different autoimmune diseases, and the biotech is now planning the pivotal trials that ...
View ArticleEndpoints Livestream: What happens when AI thinks in ways we can’t understand?
We’re back for the second time this week! Tomorrow on Post-Hoc Live, we’re going to bring in a guest I’ve wanted to have on for a long time, to talk about how biotech models of ...
View ArticleNuvation Bio scores first FDA approval for new lung cancer drug
Nuvation Bio on Wednesday won FDA approval with its first commercialized drug, Ibtrozi, for advanced ROS1-positive non-small cell lung cancer (NSCLC). The approval of Ibtrozi, known generically as...
View ArticleHouse appropriators call for FDA tweaks on accelerated approvals, biosimilars
House appropriators are calling on the FDA to boost biosimilar access and better align its accelerated approval pathway across its drug and biologics centers. A House Appropriations Committee report...
View ArticleOrganoid startup raises $21M to test drugs and vaccines in human lymph...
Parallel Bio, a startup that figured out how to grow miniature human lymph nodes in a dish, has raised $21 million in Series A funding for its alternative to animal models, the company told ...
View ArticleFederal officials plan listening sessions to address drug competition
The Federal Trade Commission and Department of Justice plan to have three listening sessions focused on how to lower drug prices through enhanced market competition. The sessions will center on pharma...
View ArticleHHS urges against reviving Chamber of Commerce’s IRA suit
The Trump administration is defending another Biden-era court win in a case challenging Medicare price negotiations under the Inflation Reduction Act. The government on Wednesday urged the US Court of...
View Article